Janssen Pharmaceuticals and Bavarian Nordic closed a collaboration and license agreement to jointly develop their respective technologies, MVA-BN® and AdVac® technology, for the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections. The goal is to develop a therapeutic vaccine to intercept HPV infection-related disease, particularly in women and men who are diagnosed with HPV early, by enhancing the ability of the immune system to treat chronic infections and prevent progression to cancer.

Janssen will conduct all clinical development and, subject to regulatory approval, will be responsible for registration, distribution and commercialization of the potential combination vaccine worldwide.